CD274 and small cell lung carcinoma: Some phase 1/2 studies (NCT02621398, NCT02434081, NCT02402920, NCT03585998) also revealed that the α-PD-1/PD-L1 inhibitor plus concurrent chemoradiotherapy combination was tolerable in patients with advanced NSCLC and limited stage SCLC, with promising clinical efficacy (14–16).